バイオの戯言

＜Antisense Pharma＞
・Antisense Pharma presents at German Science Day to business and daily press, plus investors（2012.1.26）

＜Antisense Therapeutics＞
・Appendix 3B（2012.1.23）
・Appendix 4C - Quarterly Cashflow Report（2012.1.26）

＜Cerulean Pharma＞
・Cerulean Pharma Appoints Chief Business Officer（2012.1.23）

＜enGene＞
・World-leading Inflammatory Bowel Disease Clinical Investigators Join ENGENEʼs Newly Established Clinical Advisory Board（2012.1.24）

＜Generex Biotechnology＞
・Generex Secures Commitments for $3.6M Capital Raise（2012.1.25）

＜Genesis Research and Development Corporation＞
・Genesis to Merge With Mariposa（2012.1.12）

＜Integrated DNA Technologies＞
・IDT Genome-wide qPCR Primers Ideal for Use with Intercalating Dyes（2012.1.20）

＜Marina Biotech＞
・Marina Biotech Receives Notice of Acceptance for Patent Broadly Covering Its Unlocked Nucleobase Analog (UNA) Technology（2012.1.23）
・Marina Biotech Starts Cohort 2 of Its Phase 1b START-FAP Clinical Trial of CEQ508（2012.1.25）

＜OPKO Health＞
・OPKO Health Acquires Next Generation Prostate Cancer Tests（2012.1.23）
・OPKO Health to Acquire Chilean Pharmaceutical Company（2012.1.23）

＜Pharmaxis＞
・Conference Call Details - December 2011 Quarterly Report to Shareholders（2012.1.23）
・Recording of Investor Conference Call - 25 January 2012（2012.1.25）

＜Prosensa＞
・Prosensa rondt succesvol € 23 miljoen financiering af, geleid door het Amerikaanse New Enterprise Associates（2012.1.25）
・Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates（2012.1.25）

＜RXi Pharmaceuticals＞（Galena Biopharmaの記事も記載）
・Galena Biopharma to Present at the World Cancer Immunotherapy Conference（2012.1.24）

＜Silence Therapeutics＞
・Holding in Company（2012.1.23）
・Holding in Company（2012.1.26）

＜アンジェスMG＞
・虚血性疾患治療剤「コラテジェン」を用いた学術研究が英国でグラントに採択 −ブリストル大学による静脈グラフト病に対するHGF遺伝子治療研究−（2012.1.25）
・メディキットとアンジェス MGがNF-κBデコイオリゴを用いた新規医療機器の開発製造販売契約を締結 −血管再狭窄抑制に有効な薬剤塗布型PTAバルーンカテーテルの開発−（2012.1.26）

＜石原産業＞
・in vivoのApplication（Rat lumbar dorsal hornへのsiRNA導入）を追加（2012.1.20）

RNA therapeutics: beyond RNA interference and antisense oligonucleotides.
Kole R, Krainer AR, Altman S. Nat Rev Drug Discov. 2012

Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles.
Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Mol Ther. 2012 Jan 17

Supramolecular assemblies in functional siRNA delivery: Where do we stand?
Aliabadi HM, Landry B, Sun C, Tang T, Uludağ H. Biomaterials. 2012 Mar

Critical Issues In Delivery of RNAi Therapeutics In Vivo.
Rivera S, Yuan F. Curr Pharm Biotechnol. 2012 Sep

Cholesterol-Dependent Macropinocytosis and Endosomal Escape Control the Transfection Efficiency of Lipoplexes in CHO Living Cells.
Cardarelli F, Pozzi D, Bifone A, Marchini C, Caracciolo G. Mol Pharm. 2012 Jan

＜Alnylam Pharmaceuticals＞
・Alnylam Files Patent Infringement Suit Against Tekmira（2012.1.17）
・Alnylam to Restructure Organization, Aligning Resources with Focus on Highest Value Pipeline Opportunities in “Alnylam 5x15™” Product Strategy（2012.1.19）

＜Generex Biotechnology＞
・Generex Subsidiary Antigen Express Featured on SNN Stock News Now; Highlights Advantages of Ii-Key Platform Technology for Cancer Immunotherapy（2012.1.17）

＜Genta＞
・New Clinical Trial Confirms the Activity of Tesetaxel in Patients with Advanced Gastric Cancer（2012.1.19）

＜Idera Pharmaceuticals＞
・Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Patients with Advanced Non-Small Cell Lung Cancer（2012.1.20）

＜Lorus Therapeutics＞
・LORUS THERAPEUTICS REPORTS SECOND QUARTER RESULTS FOR FISCAL YEAR 2012（2012.1.13）

＜OncoGenex Technologies＞
・OncoGenex Announces Presentation of OGX-427 Data at the ASCO 2012 Genitourinary Cancers Symposium（2012.1.19）

＜Polyplus-transfection＞
・Polyplus-transfection launches the next generation PEI transfection reagent for bioproduction（2012.1.18）

＜RXi Pharmaceuticals＞（Galena Biopharmaの記事も記載）
・Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence（2012.1.20）

＜Tekmira Pharmaceuticals＞
・Tekmira Provides Periodic Update to Litigation（2012.1.17）

＜アンジェスMG＞
・IR情報/IRスケジュールを更新しました（2012.1.19）

＜Alnylam Pharmaceuticals＞
・Alnylam Provides Key 2012 Goals for RNAi Therapeutics Pipeline（2012.1.8）

＜Mesoblast＞（Angioblast Systemsを買収）
・Presentation to 30th Annual JP Morgan Healthcare Conference in USA（2012.1.11）

＜Antisense Pharma＞
・Special Issue: Transforming Growth Factor Beta (TGF-β) as a Target in Oncology（2012.1.11）
・Antisense Pharma terminates Phase III trial SAPPHIRE (HGG 2nd line) due to slow patient recruitment（2012.1.11）

＜Benitec＞
・Pfizer and Tacrere Publish Pre-Clinical Results With Benitec’s ddRNAi（2012.1.9）
・Clinical study confirms Benitec’s gene-silencing technology is safe and effective in Gradalis’ cancer vaccine（2012.1.10）

＜BioMolecular Therapeutics＞
・BioMolecular Therapeutics signs research contract with Samyang Inc. on RNAi trigger development（2012.1.10）

＜DNA THERAPEUTICS＞
・the patients enrolled in the 1st dose cohort of the DRIIM trial completed 2 week course of treatment, without toxicity.（2012.1.3）
・US Patent and Trademark Office (USPTO) has notified its decision to grant the 3rd Dbait patent for its standalone treatment (monotherapy) in cancer. This approval greatly strengthens the company's IP assets, and further secures the development of its lead product.（2012.1.10）

＜Idera Pharmaceuticals＞
・Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck（2012.1.9）

＜Marina Biotech＞
・Marina Biotech, Inc. Provides Update on Its Broad Nucleic Acid-Based Drug Discovery Platform and 2012 Goals（2012.1.10）

＜Silence Therapeutics＞
・Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate delivery of novel microRNA-based therapeutics（2012.1.9）

＜Tekmira Pharmaceuticals＞
・Tekmira Granted an Injunction Against Certain Individuals From AlCana Technologies by the Supreme Court of British Columbia（2012.1.10）

＜アンジェスMG＞
・Rare Hawaiian Organic White Honey（ホワイトハニー）の独占的供給の合意について −医薬部外品、化粧品の製品開発−（2012.1.10）

＜Alnylam Pharmaceuticals＞
・Alnylam to Webcast Presentation at 30th Annual J.P. Morgan Healthcare Conference 2012（2012.1.4）
・Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia（2012.1.4）
・Alnylam and Arrowhead Form Collaboration and Licensing Agreement（2012.1.5）
・Regulus Therapeutics to Present microRNA Platform and Pipeline Updates at Two Leading Scientific Conferences（2012.1.5）
・Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis（2012.1.6）

＜Arrowhead Research＞
・Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial（2012.1.4）
・Alnylam and Arrowhead Form Collaboration and Licensing Agreement
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) –
– Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –（2012.1.5）

＜AVI BioPharma＞
・AVI BioPharma Data Safety Monitoring Board Reports No Safety Concerns Identified in Phase IIb DMD Clinical Trial, Recommends Continuation of Trial（2012.1.4）

＜Dicerna Pharmaceuticals＞
・Dicerna Pharmaceuticals Appoints Life Sciences Executive James B. Weissman to Chief Business Officer（2012.1.4）

＜Generex Biotechnology＞
・Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy（2012.1.3）
・Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference（2012.1.4）
・Generex Subsidiary Antigen Express Available for Partnering & Collaboration Meetings at the 2012 JPMorgan Healthcare Conference（2012.1.5）

＜Genta＞
・Genta Incorporated To Present at the 5th Annual OneMedForum in San Francisco（2012.1.3）

＜Isis Pharmaceuticals＞
・Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy（2012.1.4）
・ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein（2012.1.5）
・Regulus Therapeutics to Present microRNA Platform and Pipeline Updates at Two Leading Scientific Conferences（2012.1.5）
・Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation（2012.1.5）

＜Marina Biotech＞
・Marina Biotech, Inc. to Present at Biotech Showcase 2012（2012.1.3）
・Marina Biotech, Inc. Closes Previously Announced $5 Million Financing（2012.1.6）

＜miRagen Therapeutics＞
・miRagen Therapeutics to Present at Biotech Showcase 2012（2012.1.5）

＜Mirna Therapeutics＞
・Mirna Therapeutics to Present at Biotech Showcase 2012（2012.1.5）

＜OncoGenex Technologies＞
・OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology（2012.1.4）

＜OPKO Health＞
・OPKO Health to Present at the 30th Annual J.P. Morgan Healthcare Conference（2012.1.6）

＜Quark Pharmaceuticals＞
・Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007（2012.1.4） ← QPI-1007：caspase-2を標的とするsiRNA製剤

＜Regulus Therapeutics＞
・Regulus Therapeutics to Present microRNA Platform and Pipeline Updates（2012.1.5）

＜RXi Pharmaceuticals＞（Galena Biopharmaの記事も記載）
・Galena Biopharma to Present at the Biotech Showcase 2012 Conference（2012.1.5）
・Galena Biopharma Announces Investigational New Drug Approval for Phase 2 Trial for NeuVax(TM) (E75 + GM-CSF) Combined With Herceptin(R) (trastuzumab)（2012.1.5）

＜Silence Therapeutics＞
・Research and Development Collaboration Update（2012.1.6）

＜Tekmira Pharmaceuticals＞
・Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data（2012.1.4）